Dr Raj Chovatiya (Northwestern University Feinberg School of Medicine, USA) and his colleagues investigated whether there is an association between the risk for osteoporosis or pathologic fractures and pemphigus or bullous pemphigoid patients, and also looked for fracture predictors. The authors analysed data from over 198 million people of all ages that received treatment in emergency rooms all over the USA from 2006-2012. Among these adults and children were 4,502 cases of pemphigus and 8,863 of bullous pemphigoid.
After adjusting for risk factors such as sex, age, income, previous long-term steroids, and insurance, there was still a significantly elevated risk of osteoporosis and pathologic fractures in pemphigus patients. The researchers found a 2.54-fold elevated relative risk for osteoporosis, a 2.2-fold elevated relative risk for osteopenia, a 2.04-fold elevated risk for general pathologic fractures, and a 1.46-fold elevated risk for pathologic femur or verbal fractures. The odds ratio for osteomalacia was very high, at 29.7. In patients with bullous pemphigoid, the odds for pathologic fractures and osteoporosis were also elevated (1.52 and 1.55).
The risks for osteoporosis and pathologic fractures were further increased by a history of long-term steroid use. In addition, female sex and increasing number of chronic diseases were identified as significant predictors for any fracture. Pemphigus or bullous pemphigoid patients with fractures had increased hospital admission rates. The total costs of care were significantly higher when a fracture occurred in these patients. Due to these results, the study authors concluded that there might be a possible benefit of fracture prevention and osteoporosis screening for patients suffering from these diseases.
1. Chovatiya R et al. ePoster No. 8514, AAD Annual Meeting, 1-5 March 2019, Washington DC, USA.
Posted on
Previous Article
« JAK inhibitors: a pathogenesis-directed therapy for alopecia areata Next Article
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis »
« JAK inhibitors: a pathogenesis-directed therapy for alopecia areata Next Article
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis »
Table of Contents: AAD 2019
Featured articles
Letter from the Editor
Interview with AAD president Prof. George J. Hruza
Late-Breakers
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab – a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
Atopic Dermatitis: Many New Therapies in the Pipeline
New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
What's New and Hot in Acne
Should we use more hormonal therapy?
Pearls of the Posters
Pemphigus patients prone to osteoporosis
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma
Related Articles
October 4, 2021
ESMO 2021 Highlights Podcast
October 22, 2021
‘Diligent’ dermatology care needed in organ-transplant recipients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com